<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32770027</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a 1-year survival prognosis estimation model for Amyotrophic Lateral Sclerosis using manifold learning algorithm UMAP.</ArticleTitle><Pagination><StartPage>13378</StartPage><MedlinePgn>13378</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13378</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-70125-8</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is an inexorably progressive neurodegenerative condition with no effective disease modifying therapies. The development and validation of reliable prognostic models is a recognised research priority. We present a prognostic model for survival in ALS where result uncertainty is taken into account. Patient data were reduced and projected onto a 2D space using Uniform Manifold Approximation and Projection (UMAP), a novel non-linear dimension reduction technique. Information from 5,220 patients was included as development data originating from past clinical trials, and real-world population data as validation data. Predictors included age, gender, region of onset, symptom duration, weight at baseline, functional impairment, and estimated rate of functional loss. UMAP projection of patients shows an informative 2D data distribution. As limited data availability precluded complex model designs, the projection was divided into three zones with relevant survival rates. These rates were defined using confidence bounds: high, intermediate, and low 1-year survival rates at respectively [Formula: see text] ([Formula: see text]), [Formula: see text] ([Formula: see text]) and [Formula: see text] ([Formula: see text]). Predicted 1-year survival was estimated using zone membership. This approach requires a limited set of features, is easily updated, improves with additional patient data, and accounts for results uncertainty.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grollemund</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratoire d'Informatique de Paris 6, Sorbonne Universit&#xe9;, Paris, 75005, France. vincent.grollemund@lip6.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FRS Consulting, Paris, 75009, France. vincent.grollemund@lip6.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chat</LastName><ForeName>Ga&#xe9;tan Le</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>FRS Consulting, Paris, 75009, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Secchi-Buhour</LastName><ForeName>Marie-Sonia</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>FRS Consulting, Paris, 75009, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delbot</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratoire d'Informatique de Paris 6, Sorbonne Universit&#xe9;, Paris, 75005, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanterre Universit&#xe9;, Modal'X, Nanterre, 92014, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat-Peyre</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Laboratoire d'Informatique de Paris 6, Sorbonne Universit&#xe9;, Paris, 75005, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanterre Universit&#xe9;, Modal'X, Nanterre, 92014, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bede</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, 75005, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, APHP, Paris, 75013, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computational Neuroimaging Group, Trinity College, Dublin, D02 PN40, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre-Fran&#xe7;ois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, 75005, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Piti&#xe9;-Salp&#xea;tri&#xe8;re University Hospital, APHP, Paris, 75013, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Antnagelvin Hospital, Northern Ireland Center for Stratified Medecine, Biomedical Sciences Research Institute Ulster University, C-TRIC, Londonderry, BT47 6SB, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069558" MajorTopicYN="N">Unsupervised Machine Learning</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32770027</ArticleId><ArticleId IdType="pmc">PMC7414917</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-70125-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-70125-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P. Primary lateral sclerosis: A distinct entity or part of the ALS spectrum? Amyotroph. Lateral Scler. Frontotemporal Degen. 2019;20:133&#x2013;145. doi: 10.1080/21678421.2018.1550518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550518</ArticleId><ArticleId IdType="pubmed">30654671</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. Frontotemporal Degen. 2014;15:453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: A prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry. 2015;87:628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127&#x2013;1138. doi: 10.1016/s1474-4422(14)70129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, et al. Predicting prognosis in amyotrophic lateral sclerosis: A simple algorithm. J. Neurol. 2015;262:1447&#x2013;1454. doi: 10.1007/s00415-015-7731-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7731-6</ArticleId><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: A 15-year experience. Neurodegener. Dis. 2012;12:81&#x2013;90. doi: 10.1159/000341316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000341316</ArticleId><ArticleId IdType="pubmed">22922503</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011;76:1263&#x2013;1269. doi: 10.1212/wnl.0b013e318214359f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e318214359f</ArticleId><ArticleId IdType="pubmed">21464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf J, et al. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients&#x2014;Data from a population-based registry. BMC Neurol. 2014;14:197. doi: 10.1186/s12883-014-0197-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-014-0197-9</ArticleId><ArticleId IdType="pmc">PMC4189670</ArticleId><ArticleId IdType="pubmed">25280575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, et al. Machine learning in amyotrophic lateral sclerosis: Achievements, pitfalls, and future directions. Front. Neurosci. 2019;13:135. doi: 10.3389/fnins.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6403867</ArticleId><ArticleId IdType="pubmed">30872992</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, et al. Complete hazard ranking to analyze right-censored data: An als survival study. PLoS Comput. Biol. 2017;13:e1005887. doi: 10.1371/journal.pcbi.1005887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005887</ArticleId><ArticleId IdType="pmc">PMC5749893</ArticleId><ArticleId IdType="pubmed">29253881</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Survival prediction in amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. 2017;17:1. doi: 10.1186/s12883-017-0854-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0854-x</ArticleId><ArticleId IdType="pmc">PMC5393027</ArticleId><ArticleId IdType="pubmed">28412941</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones BK, Greene CS, et al. Semi-supervised learning of the electronic health record for phenotype stratification. J. Biomed. Inform. 2016;64:168&#x2013;178. doi: 10.1016/j.jbi.2016.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.007</ArticleId><ArticleId IdType="pubmed">27744022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M-L, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS ONE. 2017;12:e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/s1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>h.&#xa0;Taguchi, Y., Iwadate, M. &amp; Umeyama, H. Heuristic principal component analysis-based unsupervised feature extraction and its application to gene expression analysis of amyotrophic lateral sclerosis data sets. In 2015 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), 10.1109/cibcb.2015.7300274 (IEEE, 2015).</Citation></Reference><Reference><Citation>Tang M, et al. Model-based and model-free techniques for amyotrophic lateral sclerosis diagnostic prediction and patient clustering. Neuroinformatics. 2019;17:407&#x2013;421. doi: 10.1007/s12021-018-9406-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-018-9406-9</ArticleId><ArticleId IdType="pmc">PMC6527505</ArticleId><ArticleId IdType="pubmed">30460455</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes, L., Healy, J. &amp; Melville, J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:1802.03426 (2018).</Citation></Reference><Reference><Citation>Lenglet T, et al. A phase ii&#x2013;iii trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, et al. Pentoxifylline in als: A double-blind, randomized, multicenter, placebo-controlled trial. Neurology. 2006;66:88&#x2013;92. doi: 10.1212/01.wnl.0000191326.40772.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000191326.40772.62</ArticleId><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pro-act database. https://nctu.partners.org/ProACT/Home/Index. Accessed 01 Jan 2020.</Citation></Reference><Reference><Citation>Querin G, et al. Spinal cord multi-parametric magnetic resonance imaging for survival prediction in amyotrophic lateral sclerosis. Eur. J. Neurol. 2017;24:1040&#x2013;1046. doi: 10.1111/ene.13329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13329</ArticleId><ArticleId IdType="pubmed">28586096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing Clinical Research. Philadelphia: Lippincott Williams &amp; Wilkins; 2006.</Citation></Reference><Reference><Citation>Elamin M, et al. Cognitive changes predict functional decline in ALS: A population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597. doi: 10.1212/wnl.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney RK, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology. 2005;65:1774&#x2013;1777. doi: 10.1212/01.wnl.0000188759.87240.8b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188759.87240.8b</ArticleId><ArticleId IdType="pubmed">16344521</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Alruwaili ARS, Henderson RD, McCombe PA. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: Frequency of abnormality and effect on survival. J. Neurol. Sci. 2017;376:16&#x2013;23. doi: 10.1016/j.jns.2017.02.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.02.061</ArticleId><ArticleId IdType="pubmed">28431606</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartagno M, Carpenter JR. Multiple imputation for IPD meta-analysis: Allowing for heterogeneity and studies with missing covariates. Stat. Med. 2016;35:2938&#x2013;54. doi: 10.1002/sim.6837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6837</ArticleId><ArticleId IdType="pmc">PMC5064632</ArticleId><ArticleId IdType="pubmed">26681666</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirola A, et al. The prognostic value of spirometric tests in amyotrophic lateral sclerosis patients. Clin. Neurol. Neurosurg. 2019;184:105456. doi: 10.1016/j.clineuro.2019.105456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2019.105456</ArticleId><ArticleId IdType="pubmed">31382080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, et al. Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: A retrospective observational study. Eur. J. Neurol. 2016;23:1117&#x2013;1125. doi: 10.1111/ene.12994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12994</ArticleId><ArticleId IdType="pubmed">27016147</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, et al. Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort. J. Neurol. Neurosurg. Psychiatry. 2019;90:666&#x2013;673. doi: 10.1136/jnnp-2018-319611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319611</ArticleId><ArticleId IdType="pubmed">30630957</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a c9orf72 repeat expansion: A population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/s1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Iyer PM, Finegan E, Omer T, Hardiman O. Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patterns. NeuroImage Clin. 2017;15:653&#x2013;658. doi: 10.1016/j.nicl.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.06.010</ArticleId><ArticleId IdType="pmc">PMC5479963</ArticleId><ArticleId IdType="pubmed">28664036</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, et al. Survival prediction models in motor neuron disease. Eur. J. Neurol. 2019;26:1143&#x2013;1152. doi: 10.1111/ene.13957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13957</ArticleId><ArticleId IdType="pubmed">30920076</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T, Jung HH. RandomForest4life: A random forest for predicting ALS disease progression. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:444&#x2013;452. doi: 10.3109/21678421.2014.893361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.893361</ArticleId><ArticleId IdType="pubmed">25141076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko, K.&#xa0;D., El-Ghazawi, T., Kim, D. &amp; Morizono, H. Predicting the severity of motor neuron disease progression using electronic health record data with a cloud computing big data approach. In 2014 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology, 10.1109/cibcb.2014.6845506 (IEEE, 2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285703</ArticleId><ArticleId IdType="pubmed">25580472</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ffner R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat. Biotechnol. 2015;33:51. doi: 10.1038/nbt.3051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3051</ArticleId><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2016;3:866&#x2013;875. doi: 10.1002/acn3.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.348</ArticleId><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahandideh S, et al. Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;19:294&#x2013;302. doi: 10.1080/21678421.2017.1418003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1418003</ArticleId><ArticleId IdType="pubmed">29260584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Kim RB, Coan GS, Mitchell CS. Unraveling the complexity of amyotrophic lateral sclerosis survival prediction. Front. Neuroinform. 2018;12:36. doi: 10.3389/fninf.2018.00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fninf.2018.00036</ArticleId><ArticleId IdType="pmc">PMC6010549</ArticleId><ArticleId IdType="pubmed">29962944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Querin G, Pradat P-F. The changing landscape of motor neuron disease imaging. Curr. Opin. Neurol. 2018;31:431&#x2013;438. doi: 10.1097/wco.0000000000000569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000569</ArticleId><ArticleId IdType="pubmed">29750730</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): The tripod statement. BMC Med. 2015;13:1. doi: 10.1186/s12916-014-0241-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0241-z</ArticleId><ArticleId IdType="pmc">PMC4284921</ArticleId><ArticleId IdType="pubmed">25563062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>